PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.66%
Negative revenue growth while Healthcare median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-35.70%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
20.21%
EBIT growth of 20.21% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
20.21%
Operating income growth of 20.21% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
113.92%
Net income growth of 113.92% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
99.57%
EPS growth of 99.57% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
99.57%
Diluted EPS growth of 99.57% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
2.42%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.42%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
81.64%
OCF growth of 81.64% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
77.49%
FCF growth of 77.49% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
594.48%
5Y CAGR of 594.48% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
323.94%
3Y CAGR of 323.94% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-161.58%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-776.11%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-559.39%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
284.96%
Net income/share CAGR of 284.96% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
43.41%
5Y net income/share CAGR > 1.5x Healthcare median of 3.13%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-93.73%
Negative 3Y CAGR while Healthcare median is 3.47%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
5088.46%
Equity/share CAGR of 5088.46% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
710.77%
5Y equity/share CAGR of 710.77% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
47.80%
3Y equity/share CAGR of 47.80% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.47%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-7.35%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-3.72%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-0.42%
Negative BV/share change while Healthcare median is -0.59%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.47%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-34.39%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-20.17%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.